Arovella Therapeutics Ltd. and Imugene have achieved a successful outcome from the initial in vitro experiments conducted as part of their research
collaboration. Both companies are pleased to announce that they are progressing the research collaboration to the next phase of testing. The positive results show that the combination of Arovella's CAR19-iNKT cell therapy (ALA-101) and Imugene's onCARlytics therapy (CF33-CD19) kills solid tumour cells in vitro. The companies intend to present this early data at a conference in the near-term. The project's next stage is to test the combination in vivo (mouse models). The collaboration with Imugene opens potential new therapeutic targets for ALA-101 in solid tumours and is an exciting expansion of Arovella's pipeline. Imugene's onCARlytics platform induces solid tumour cells to express CD19 on their surface, allowing them to be targeted by therapies, such as ALA-101, that target cancer cells through CD19. Solid tumours represent 90% of diagnosed cancer cases i; as of 2021, the solid tumour market was valued at USD 210 billion. Arovella continues to progress its ALA-101 product towards first in human clinical trials for the treatment of blood cancers and is working on completing clinical manufacturing and IND-enabling studies.